Assessment of serum vascular endothelial growth factor and nail fold capillaroscopy changes in systemic lupus erythematosus with and without cutaneous manifestations

Journal of Dermatology

Volumn 39, Issue 1, 2012, Pages 52-57

  Moneib, Hoda A ^a   Salem, Samar A M ^a   Aly, Dalia G ^a,b   Khedr, Heba T M ^b   Wafaey, Hanaa A ^b   Hassan, Hanan E ^c  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

angiogenesis; cutaneous lupus erythematosus; nail fold capillaroscopy; systemic lupus erythematosus; vascular endothelial growth factor; vasculogenesis

Indexed keywords

VASCULOTROPIN;

ADOLESCENT; ADULT; ANGIOGENESIS; ARTICLE; CAPILLAROSCOPY; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NAIL FOLD CAPILLAROSCOPY; PILOT STUDY; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICROSCOPIC ANGIOSCOPY; MIDDLE AGED; NAILS; NEOVASCULARIZATION, PATHOLOGIC; PILOT PROJECTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84855359276     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01322.x     Document Type: Article

References (29)

1. Facina AS, Pucinelli MLC, Vasconcellos MRA, et al. Capillaroscopy findings in lupus erythematosus. An Bras Dermatol 2006; 81 (6): 523-528.
2. Callen JP,. Update on the management of cutaneous lupus erythematosus. Br J Dermatol 2004; 151: 731-736. (Pubitemid 39482105)
3. Bujan S, Ordi-Ros J, Paredes J, et al. Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. Ann Rheum Dis 2003; 62: 859-865. (Pubitemid 37026497)
4. Kuryliszyn-Moskal A, Klimivk PA, Sierakowski S, Ciolkiewicz M,. Vascular endothelial growth factor in SLE: relationship to disease activity, systemic organ manifestations, and nail fold capillaroscopic abnormalities. Arch Immunol Ther Exp 2007; 55 (3): 179-185. (Pubitemid 46953938)
5. Koch AE,. Angiogenesis is a target in rheumatoid arthritis. Ann Rheum Dis 2003; 62 (Suppl 2): ii60-ii67.
6. Hurrairah H, Ferro A,. The role of endothelium in the control of vascular function. Int J Clin Pract 2004; 58: 173-183. (Pubitemid 38425748)
7. Josko J, Gwozdzb B, Jedrzejowska-Syzpulka H, Hendryk S,. Vascular endothelial growth factor (VEGF) and it's effect on angiogenesis. Med Sci Monit 2000; 6: 1047-1052.
8. Cutolo M, Sulli A, Secchi ME, Pizzorni C,. [Capillaroscopy and rheumatic diseases: state of the art]. German Z Rheumatol 2006; 65: 290-296. (Pubitemid 44124539)
9. Ingegnoli F, Zeni S, Meani L, et al. Evaluation of nail fold video capillaroscopic abnormalities in patients with SLE. J Clin Rheumatol 2005; 11: 295-298.
10. Riccieri V, Spadaro A, Ceccarelli F, Scrivo R, Germano V, Valesini G,. Nailfold capillaroscopy changes in systemic lupus erythematosus: correlations with disease activity and autoantibody profile. Lupus 2005; 14: 521-525. (Pubitemid 41161082)
11. Kuryliszyn-Moskal A, Klimivk PA, Sierakowski S, Ciolkiewicz M,. Clinical significance of nail fold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity. Scand J Rheumatol 2009; 38: 38-45.
12. Salem SA, Farouk HM, Mostafa AA, et al. Keratinocyte and lymphocyte apoptosis: relation to disease outcome in systemic lupus erythematosus patients with and without cutaneous manifestations. Eur J Dermatol 2010; 20 (1): 35-41.
13. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277. (Pubitemid 13221242)
14. Liang MH, Socher SA, Larson MG, Schur PH,. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1112.
15. Agneta S, Anta A, Izabella N,. Computer based quantitative analysis of capillary abnormalities in systemic sclerosis. Ann Rheum Dis 1996; 55: 52-56.
16. Clancy R, Marder G, Martin V, et al. Circulating activated endothelial cells in systemic lupus erythematosus. Further evidence for diffuse vasculopathy. Arthritis Rheum 2001; 44: 1203-1208. (Pubitemid 32433629)
17. Koch AE,. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis 2000; 59 (Suppl 1): 565-571.
18. Jaramillo F, Brieva J, Sanchez A,. Observaciones en 65 pacientes com desordenes del tejido conectivo. Acta Med Colomb 1998; 13: 129-138.
19. Guyton AC,. Human Physiology and Mechanisms of Rheumatic Diseases, 5th edn. WB Saurders, Boston 2002; 212-217.
20. Calamia KT, Balabanova M,. Vasculitis in systemic lupus erythematosus. Clin Dermatol 2004; 22: 148-156.
21. Kikuchi KM, Kubo T, Kadona N, et al. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998; 139 (6): 1049-1451.
22. Navarro C, Candia-Zuninga L, Silveira LH,. Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary anti phospholipid syndrome. Lupus 2002; 11 (1): 21-24. (Pubitemid 34178115)
23. Robak E, Woz′niacka A, drzejewska A, et al. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 2002; 11: 348-355. (Pubitemid 34760632)
24. Robak E, Drzejewska A, Robak T,. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediators Inflamm 2003; 12 (5): 293-298. (Pubitemid 37392901)
25. Avihingsanon Y, Phumesin P, Benjachat T, Akkasilpa S,. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int 2006; 69 (4): 747-753. (Pubitemid 43237645)
26. Bodolay E, Koch AE, Kim J, et al. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 2002; 6: 357-376. (Pubitemid 44133956)
27. Belmont HM, Levartovshy D, Goel A,. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1810-1816. (Pubitemid 27452531)
28. 1 murine systemic lupus erythematosus Model. Clin Cancer Res 2005; 11: 407.
29. Blau HM, Banfi A,. The well-tempered vessel. Nature Med 2001; 7: 532-534. (Pubitemid 32448310)